ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CYP17A1-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CYP17A1-inhibitor
20
trial(s) found.
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Glandore - Ashford Cancer Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06691984
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
bispecific T-cell engager,STEAP1-targeting
taxane
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
NCT06551324
Advanced
Phase 3
Recruiting
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (
MEVPRO-1
)
CYP17A1 inhibitor
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
taxane
Castrate-resistant prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT06520345
Advanced
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
177Lu-anti-PSMA-radioconjugate
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06136650
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (
5684-004
)
CYP11A1 inhibitor
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
Prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital
NCT06136624
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003) (
5684-003
)
CYP11A1 inhibitor
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2830 - Dubbo - Dubbo Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT06120491
Advanced
Phase 3
Recruiting
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) (
EvoPAR-PR01
)
PARP1-selective inhibitor
placebo
+ CYP17A1 inhibitor
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (TERMINATED)
2031 - Randwick - Prince of Wales Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Glandore - Ashford Cancer Centre
NCT05818683
Advanced
Phase 1
Recruiting
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer (
CR109321
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,KLK2-targeting
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05413421
Advanced
Phase 1
Recruiting
An Open-Label, Phase 1/1b Study of ORIC-944 As a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer (
ORIC-944-01
)
PRC2 complex inhibitor
+ CYP17A1 inhibitor
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05367440
Advanced
Phase 1 / Phase 2
Recruiting
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (
PETRANHA
)
PARP1-selective inhibitor
+ CYP17A1 inhibitor
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04947189
Advanced
Phase 1 / Phase 2
Recruiting
4CAST
: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer
CYP17A1 inhibitor
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04597411
Advanced
Phase 1
Recruiting
AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (
PSMA-617-100
)
radioligand,PSMA-targeting
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04221542
Advanced
Phase 1
Recruiting
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
bispecific T-cell engager,STEAP1-targeting
+ CYP17A1 inhibitor
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
NCT02960022
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (
9785-CL-0123
)
antiandrogen,nonsteroidal,second generation
+ CYP17A1 inhibitor
Prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)
2485 - Tweed Heads - The Tweed Hospital (COMPLETED)
2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ CYP17A1 inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ CYP17A1 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
NCT05551117
Advanced
Phase 2
Completed
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (
Tamarack
)
anti-B7H3 antibody-drug conjugate
+ CYP17A1 inhibitor
Anal cancer
Carcinoma
Castrate-resistant prostate cancer
Head and neck squamous cell carcinoma
Laryngeal squamous cell carcinoma
Melanoma
Non-small cell lung cancer
Prostate cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Squamous cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05288166
Advanced
Phase 3
Active not recruiting
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer (
CYCLONE-3
)
CDK4/6 inhibitor
CYP17A1 inhibitor
glucocorticoid
placebo
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
SA
5037 - Glandore - Ashford Cancer Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
+ CYP17A1 inhibitor
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Completed (1)
Active not recruiting (1)
Unknown (1)
Recruitment Country and State
NSW (19)
VIC (16)
QLD (10)
SA (5)
WA (4)
NZ (4)
TAS (2)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (4)
Phase 2 (3)
Phase 3 (8)
Trial Type
Advanced (20)
Cancer Therapy Class
CYP17A1
100%
androgen axis
100%
AR
90%
PARP
20%
PD-1/PD-L1
15%
STEAP1
10%
CYP11A1
10%
PARP1-selective
10%
PD-1
10%
VEGF
10%
EZH2
5%
KLK2
5%
PRC2 complex
5%
PSMA
5%
HIF2a
5%
TIGIT
5%
HMG-CoA reductase
5%
oestrogen axis
5%
B7H3
5%
CDK4
5%
CDK6
5%
AXL
5%
KIT
5%
MET
5%
PD-L1
5%
RET
5%
ROS1
5%
VEGFR
5%
VEGFR2
5%
Facility
2109 - North Ryde - Macquarie University Hospital (8)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
3168 - Clayton - Monash Medical Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
2076 - Wahroonga - Sydney Adventist Hospital (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
5037 - Glandore - Ashford Cancer Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (2)
4215 - Southport - Tasman Oncology (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
7000 - Hobart - Royal Hobart Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3051 - Melbourne - Australian Prostate Centre (1)
6150 - Murdoch - GenesisCare Murdoch (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2830 - Dubbo - Dubbo Base Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
4032 - Chermside - The Prince Charles Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2217 - Kogarah - St George Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
Cancer Type
Cancer
Solid tumour
Male genital cancers
Prostate cancer
Urogenital cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Breast adenocarcinoma
Breast cancer
Triple-negative breast cancer
Anal cancer
Carcinoma
Gastrointestinal cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Laryngeal squamous cell carcinoma
Lower gastrointestinal cancer
Lung cancer
Melanoma
Neuroendocrine carcinoma
Non-small cell lung cancer
Respiratory tract cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Squamous cell carcinoma
Thoracic cancer
Differentiated thyroid carcinoma
Endocrine gland cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy